28 results
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
17 Jan 24
Current report (foreign)
4:30pm
reviewed Gracell ADS price targets for the Gracell ADSs in Wall Street research analyst reports publicly available as of December 22, 2023 (the last … trading day before the public announcement of the Transaction), which indicated low and high share price targets for Gracell ranging from $7.00
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
14 Nov 23
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
6:04am
technology can be applied to many targets for the treatment of solid tumors.
About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical
F-3/A
GRCL
Gracell Biotechnologies Inc
12 Sep 23
Shelf registration (foreign) (amended)
4:12pm
technology can be applied to many targets for the treatment of solid tumors. Additionally, with donor-derived CAR technique, we are developing an allogeneic
F-3
GRCL
Gracell Biotechnologies Inc
24 Aug 23
Shelf registration (foreign)
4:03pm
targets for the treatment of solid tumors. Additionally, with donor-derived CAR technique, we are developing an allogeneic CAR-T cell therapy program
6-K
EX-99.2
GRCL
Gracell Biotechnologies Inc
7 Aug 23
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8:07am
conventional lymphodepletion CAR2 Tumor antigen CAR targets malignant cells and enables wide applicability for different cancers CD7 CAR Targets
6-K
EX-99.1
ensiexg7nyusn2o
16 May 23
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
6:08am
6-K
EX-99.1
ivblq
16 Dec 22
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T
4:01pm
6-K
EX-99.1
axpeysq n5mac
16 Nov 22
Current report (foreign)
6:03am
6-K
EX-99.1
cnu2 eclctqvzvshdzlo
16 Nov 22
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results
6:01am
6-K
EX-99.1
oa715pt
15 Aug 22
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
8:16am
6-K
EX-99.1
v58jp2106h wjfdia05
14 Jun 22
Gracell also presented data on GC012F for treatment of B-NHL and allogeneic TruUCAR-candidate GC502 for treatment of B-ALL
6:17am
6-K
EX-99.1
mqh r2rw7r8
31 May 22
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory
6:09am
6-K
EX-99.1
eze1c4slh nu5j
17 May 22
Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results
6:13am
6-K
EX-99.1
1td ctl8ro2s
22 Feb 22
Current report (foreign)
6:19am
6-K
EX-99.1
gyn nj53q
16 Nov 21
Gracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
6:06am
20-F
nh85m7plkrio9voeob7j
23 Apr 21
Annual report (foreign)
4:04pm
424B4
vfh4vak
8 Jan 21
Prospectus supplement with pricing info
1:42pm